Clyde Williams
Pulmonary Disease · Colorado Springs, CONPI 1548329634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,723 and has fallen 95.6% since, to $76 in 2022.
Across 123 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$317
- E.r. Squibb & Sons, L.L.C.$296
- Genentech USA, Inc.$253
- Actelion Pharmaceuticals US, Inc.$217
- Grifols USA, LLC$168
- Insmed, Inc.$117
- plus $966 from 20 others
What the payments were for
- Food & beverage$2,25697%
- Education$783%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 20 | $317 |
| E.r. Squibb & Sons, L.L.C. | 11 | $296 |
| Genentech USA, Inc. | 10 | $253 |
| Actelion Pharmaceuticals US, Inc. | 10 | $217 |
| Grifols USA, LLC | 10 | $168 |
| Insmed, Inc. | 4 | $117 |
| Boehringer Ingelheim | 7 | $112 |
| GSK | 7 | $101 |
| Sunovion Pharmaceuticals Inc. | 6 | $98 |
| Shire North American Group Inc | 5 | $85 |
| United Therapeutics Corporation | 3 | $63 |
| Sanofi | 3 | $61 |
| Bayer | 3 | $59 |
| Novartis | 3 | $59 |
| AbbVie | 3 | $49 |
| Circassia Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Portola Pharmaceuticals, LLC | 2 | $28 |
| Philips North America LLC | 2 | $26 |
| UCB, Inc. | 1 | $24 |
| Merck | 2 | $23 |
| Biogen | 1 | $20 |
| Pfizer | 1 | $15 |
| Gilead | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$119
How this compares
$2,334 in reported general payments places this provider in the 65th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Colorado Springs
- Christopher MerrickColorado Springs$34K
- Andrew BoulosColorado Springs$14K
- Lalith UragodaColorado Springs$12K
- Russell LeeColorado Springs$11K
- Dheeraj DhotreColorado Springs$9K
- Timothy RummelColorado Springs$8K
- Yogesh ShresthaColorado Springs$7K
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.